Striving to Make a Big Impact in Cancer Care

Cancer remains the second-leading cause of death globally, claiming over 10 million lives every year.¹ Nearly every family around the world is touched by cancer, either through direct diagnosis or through the roles of caregivers and loved ones.² With every big impact we make towards developing treatments, we uncover more insights about cancer’s complexities, and that fuels our determination to strive for more — no matter how much trial and error it takes. The fight is far from over and even more understanding and research is required.

At Regeneron, our work toward making a big impact isn’t a single goal, it’s about all the small moments where we continue to learn and the connections and progress we make along the way. We are driven by an ambition to turn revolutionary discoveries into medicines that can transform the lives of those impacted by cancer. As we tackle one of the gravest diseases of our era, our global team is wholeheartedly devoted to meeting the needs of people with cancer and helping address the challenges faced by healthcare providers.

Key to this endeavor is collaboration. We believe in standing as a united front, working closely with patients, healthcare providers, governments and other biopharma companies with the goal of fueling transformation in cancer care.

On February 4^th, World Cancer Day, we mark the third and final year that the global cancer community is rallying behind the Union for International Cancer Control (UICC’s) theme of “Close the Care Gap.” The effort emphasizes the need to activate leaders around the world to prioritize cancer, create innovative strategies designed to confront inequity and invest resources to achieve a just and cancer-free world. 

Regeneron is committed every day to embodying a spirit of innovation that drives significant impact in cancer care.

We asked our colleagues: What does making a “big impact” mean to you and your goals for 2024?

June Lin
Executive Medical Director in Hematology, Medical Affairs

“To support effective educational efforts and continuous research, data generation and clinical development of bispecifics, a promising path for hard-to-treat cancers, to address important unmet needs for our diverse group of patients.”

Travis Gorenc
Associate Director,
Research Program Management

“Drive multiple, innovative biotherapeutics into clinical development for solid and hematologic malignancies.”

André Berot Spring
Head of Global Oncology Marketing

“My goal in 2024 is that our Regeneron science reaches as many patients as possible.”

Robert Caruano
Senior Director, Patient Advocacy (Oncology Solid Tumor)

“Ensuring the patient voice is represented in everything we do from research to patient access.”

Sandra Graham-Mason
Senior Director, Oncology Marketing

“Informing and empowering patients who live with these diseases to ask their doctors about appropriate treatment options for their case.”